NP
NeuroPace, Inc.
NPCE · NASDAQ
$14.28 +1.03% (+$0.14)
1M +1.85%
Market Cap $482.4M
P/E Ratio -
Div. Yield -
ROE 119.68%
Bulios Fair Price
$8.32
41.7% downside
Current Price
$14.28
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NPCE is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
18 /100
Expensive P/B 40.60x
P/S 4.88x
P/FFO N/A
Growth
78 /100
Growing Book val. growth 18.21%
Rev. growth 29.99%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 15.26%
Gross margin 79.63%
FCF margin 11.75%
Quality
13 /100
Poor ROA 19.71%
ROIC 18.43%
Asset turnover 1.02x
Debt
23 /100
High Int. coverage -2.14x
Debt/Equity 5.88x
Current ratio 4.94x
Stability
56 /100
Moderate EPS volatility 3.43%
Beta 1.95x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NPCE
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Joel D. Becker
Employees
220
Headquarters
Mountain View
Upcoming events
03 NOV
Earnings
Upcoming earnings report